China’s leading Biopharma event concludes successfully with 400+ industry attendees
Organised by IBC Asia, the annual Biopharma Development & Production (BDP) Week took place on 16 – 17 May 2018 at Hilton Shanghai Hongqiao Hotel.
Read more
生物技術
Lumosa Therapeutics partners with Camargo Pharmaceutical Services for the development of its analgesic in the US
Taipei, Taiwan-based Lumosa Therapeutics Co., Ltd., a company focused on developing treatments for neurological and inflammatory disease, announced recently that it had engaged Cincinnati-headquartered Camargo Pharmaceutical Services for regulatory consulting and strategic development services for LT1001 (Naldebain®, dinalbuphine sebacate IM injection) in the US.
Read more
Aslan Pharmaceuticals announces collaboration with Taiwan’s leading genomic research institute
Singapore-headquartered ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted treatments for Asia prevalent cancer types, recently announced the signing of a research collaboration agreement with Academia Sinica’s Genomic Research Centre, one of Taiwan’s leading research institutions.
Read more
“BioTaiwan’s growth is a reflection of the success of Taiwan biotech as a whole in recent years”
In Taiwan, biotech is finally booming, and new companies, service providers and manufacturing facilities are emerging to fill rapidly growing industry needs. BioSpectrum Asia recently spoke to Dr. Apo Huang, Secretary General, BioTaiwan on the current growth in the Taiwanese biotech sector.
Read more
2017台灣生技月閉幕, 逾350場媒合會, 生技月讓世界看見台灣
亞洲生技產業年度盛會–2017台灣生技月(BioTaiwan 2017)活動於6月28日-7月2日於南港舉辦，並於今日(7/2)閉幕。總計今年共有超過600家國內外指標性大廠與1310個攤位參與生技展，吸引超過9萬人次進場參觀，促成近350場的商機媒合。
Read more
OBI Pharma signs agreement with Abzena for ADC linker technology
Cambridge, UK-headquartered drug development technology and services provider Abzena plc, has signed a licensing agreement and a master services and clinical supply agreement with Taipei, Taiwan biotech OBI Pharma (TPEx: 4174) for its novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology to develop OBI’s proprietary ADC, OBI-999 and a series of further ADCs as potential treatments for cancer.
Read more